GSK Calls $90M Inhaler IP Damages 'Wildly Inflated'
Vectura Ltd. won an $89.7 million patent infringement verdict against GlaxoSmithKline LLC by relying on flawed tests and inflating damages, GSK has told a Delaware federal judge in hopes of undoing its...To view the full article, register now.
Already a subscriber? Click here to view full article